CSIMarket
 


Impel Pharmaceuticals Inc   (IMPL)
Other Ticker:  
 
 

Impel Pharmaceuticals Inc Accounts Receivables Turnover Ratio from the third quarter 2023 to the third quarter 2022

Quarterly Results, Trends, Rankings, Statistics


Impel Pharmaceuticals Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2023 to a ratio of 1.21, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the third quarter 2023. Average receivable collection period, for the Impel Pharmaceuticals Inc in Sep 30 2023 quarter, has decreased to 302 days, compared to 372 days, in the Jun 30 2023 quarter.

If we take a look into Healthcare sector 571 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2023 from 3164 to 3515.

What is Receivable Turnover Ratio?
What is Impel Pharmaceuticals Inc Selling?


What is Receivable Turnover Ratio?




IMPL Receivables Turnover Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Receivable Change 7.46 % 41.86 % 61.61 % 450.59 % 524.77 %
Y / Y Revenue Change 55.52 % 127.04 % 148.55 % - 3286.81 %
Receivable Turnover Ratio (TTM) 1.21 0.98 0.48 0.06 2.03
IMPL's Total Ranking # 3515 # 3164 # 3115 # 3271 # 2966
Average receivable collection period 301 373 762 6008 179
Seq. Receivable Change -3.16 % 8.3 % -15.64 % 21.46 % 27.85 %
Seq. Revenue Change -24.69 % 45.56 % - - 9.95 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 213
Healthcare Sector # 572
Overall Market # 3515

Receivable Turnover Ratio Statistics
High Average Low
2.03 1.11 0.06
(Sep 30 2022)   (Dec 31 2022)






Financial Statements
Impel Pharmaceuticals Inc 's Accounts Receivable $ 7 Millions Visit IMPL's Balance sheet
Impel Pharmaceuticals Inc 's Sales TTM $ 8 Millions Visit IMPL's Income Statement
Where are IMPL's Sales coming from? Visit IMPL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
IMPL's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover
Accounts Receivable Turnover for IMPL's Competitors
Receivables Turnover Ratio for IMPL's Suppliers
Accounts Receivables Turnover Ratio for IMPL's Customers

You may also want to know
IMPL's Growth Rates IMPL's Roa IMPL's Inventory Turnover Ratio IMPL's Dividend Comparisons
IMPL's Profitability Ratios IMPL's Roi IMPL's Asset Turnover Ratio IMPL's Dividend Growth
IMPL's Valuation Ratios IMPL's Roe IMPL's Financial Strength Ratios IMPL's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2023, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Sep 30 2023 Receivable at quarter ending Sep 30 2023
Apellis Pharmaceuticals Inc   3.42 $ 272.877  Millions$ 79.851  Millions
Aytu Biopharma Inc   3.40 $ 100.761  Millions$ 29.602  Millions
Arcutis Biotherapeutics Inc   3.39 $ 49.041  Millions$ 14.463  Millions
Luna Innovations Inc  3.39 $ 113.692  Millions$ 33.584  Millions
Scilex Holding Company  3.38 $ 71.315  Millions$ 21.119  Millions
Inspiremd Inc   3.38 $ 5.201  Millions$ 1.541  Millions
Royalty Pharma Plc  3.35 $ 2,324.234  Millions$ 693.353  Millions
Dermtech Inc   3.30 $ 12.651  Millions$ 3.833  Millions
Yubo International Biotech Limited  3.28 $ 0.653  Millions$ 0.199  Millions
Retractable Technologies inc   3.27 $ 51.304  Millions$ 15.676  Millions
Icad Inc  3.23 $ 21.690  Millions$ 6.723  Millions
Oncocyte Corporation  3.16 $ 5.931  Millions$ 1.878  Millions
Bioventus Inc   3.07 $ 374.333  Millions$ 121.931  Millions
Optinose Inc   3.05 $ 71.979  Millions$ 23.603  Millions
Universe Pharmaceuticals Inc  3.01 $ 32.309  Millions$ 10.729  Millions
Cumberland Pharmaceuticals Inc  2.99 $ 39.323  Millions$ 13.133  Millions
Seer Inc   2.95 $ 16.095  Millions$ 5.448  Millions
Helius Medical Technologies inc   2.94 $ 0.927  Millions$ 0.315  Millions
Nuo Therapeutics Inc   2.94 $ 0.486  Millions$ 0.165  Millions
Bioxcel Therapeutics Inc   2.93 $ 1.242  Millions$ 0.424  Millions
Verrica Pharmaceuticals Inc   2.91 $ 3.204  Millions$ 1.100  Millions
Ispecimen inc   2.90 $ 10.315  Millions$ 3.551  Millions
Alimera Sciences Inc   2.85 $ 67.294  Millions$ 23.644  Millions
Collegium Pharmaceutical Inc   2.83 $ 503.245  Millions$ 177.894  Millions
Apyx Medical Corporation  2.81 $ 49.010  Millions$ 17.441  Millions
Evofem Biosciences Inc   2.71 $ 13.560  Millions$ 5.013  Millions
Esperion Therapeutics inc   2.68 $ 102.902  Millions$ 38.392  Millions
Sientra Inc   2.67 $ 89.269  Millions$ 33.467  Millions
Chimerix Inc   2.60 $ 1.134  Millions$ 0.436  Millions
Ani Pharmaceuticals Inc  2.60 $ 449.394  Millions$ 172.980  Millions

Date modified: 2023-11-16T18:19:26+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com